Skip to main content
Have a personal or library account? Click to login
Application of the ALBI Scoring System for Mortality Outcome Prediction in Patients with Hypertrophic Cardiomyopathy Cover

Application of the ALBI Scoring System for Mortality Outcome Prediction in Patients with Hypertrophic Cardiomyopathy

Open Access
|Oct 2022

References

  1. Maron BJ. Clinical Course and Management of Hypertrophic Cardiomyopathy. N Engl J Med. 2018; 379(7): 65568. DOI: 10.1056/NEJMra1710575
  2. Maron BJ, Maron MS, Rowin EJ. Perspectives on the Overall Risks of Living With Hypertrophic Cardiomyopathy. Circulation. 2017; 135(24): 23179. DOI: 10.1161/CIRCULATIONAHA.117.027738
  3. Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, et al. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018; 138(14): 138798. DOI: 10.1161/CIRCULATIONAHA.117.033200
  4. Pujades-Rodriguez M, Guttmann OP, Gonzalez-Izquierdo A, Duyx B, O’Mahony C, Elliott P, et al. Identifying unmet clinical need in hypertrophic cardiomyopathy using national electronic health records. PLoS One. 2018; 13(1): e0191214. DOI: 10.1371/journal.pone.0191214
  5. Lorenzini M, Anastasiou Z, O’Mahony C, Guttman OP, Gimeno JR, Monserrat L, et al. Mortality Among Referral Patients with Hypertrophic Cardiomyopathy vs the General European Population. JAMA Cardiol. 2020; 5(1): 7380. DOI: 10.1001/jamacardio.2019.4534
  6. Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015; 33(6): 5508. DOI: 10.1200/JCO.2014.57.9151
  7. Abdel-Rahman O. Prognostic Value of Baseline ALBI Score Among Patients with Colorectal Liver Metastases: A Pooled Analysis of Two Randomized Trials. Clin Colorectal Cancer. 2019; 18(1): e61e8. DOI: 10.1016/j.clcc.2018.09.008
  8. Bernardi N, Chedid MF, Grezzana-Filho TJM, Chedid AD, Pinto MA, Leipnitz I, et al. Pre-transplant ALBI Grade 3 Is Associated with Increased Mortality After Liver Transplantation. Dig Dis Sci. 2019; 64(6): 1695704. DOI: 10.1007/s10620-019-5456-6
  9. Oikonomou T, Goulis L, Doumtsis P, Tzoumari T, Akriviadis E, Cholongitas E. ALBI and PALBI Grades Are Associated with the Outcome of Patients with Stable Decompensated Cirrhosis. Ann Hepatol. 2019; 18(1): 12636. DOI: 10.5604/01.3001.0012.7904
  10. Imamura T, Okamura Y, Sugiura T, Ito T, Yamamoto Y, Ashida R, et al. Clinical Significance of Preoperative Albumin-Bilirubin Grade in Pancreatic Cancer. Ann Surg Oncol. 2021. DOI: 10.1245/s10434-021-09593-9
  11. Kim MS, Kato TS, Farr M, Wu C, Givens RC, Collado E, et al. Hepatic dysfunction in ambulatory patients with heart failure: application of the MELD scoring system for outcome prediction. J Am Coll Cardiol. 2013; 61(22): 225361. DOI: 10.1016/j.jacc.2012.12.056
  12. Boon AC, Bulmer AC, Coombes JS, Fassett RG. Circulating bilirubin and defense against kidney disease and cardiovascular mortality: mechanisms contributing to protection in clinical investigations. Am J Physiol Renal Physiol. 2014; 307(2): F12336. DOI: 10.1152/ajprenal.00039.2014
  13. Targher G, Byrne CD. Circulating Markers of Liver Function and Cardiovascular Disease Risk. Arterioscler Thromb Vasc Biol. 2015; 35(11): 22906. DOI: 10.1161/ATVBAHA.115.305235
  14. Kawata T, Ikeda A, Masuda H, Komatsu S. Association Between Albumin-Bilirubin Score at Admission and In-Hospital Mortality in Patients with Acute Heart Failure. Int Heart J. 2021; 62(4): 82936. DOI: 10.1536/ihj.21-080
  15. Matsue Y, Kagiyama N, Yamaguchi T, Kuroda S, Okumura T, Kida K, et al. Clinical and Prognostic Values of ALBI Score in Patients with Acute Heart Failure. Heart Lung Circ. 2020; 29(9): 132837. DOI: 10.1016/j.hlc.2019.12.003
  16. Kunutsor SK, Bakker SJ, Gansevoort RT, Chowdhury R, Dullaart RP. Circulating total bilirubin and risk of incident cardiovascular disease in the general population. Arterioscler Thromb Vasc Biol. 2015; 35(3): 71624. DOI: 10.1161/ATVBAHA.114.304929
  17. Arques S. Human serum albumin in cardiovascular diseases. Eur J Intern Med. 2018; 52: 812. DOI: 10.1016/j.ejim.2018.04.014
  18. Lamke GT, Allen RD, Edwards WD, Tazelaar HD, Danielson GK. Surgical pathology of subaortic septal myectomy associated with hypertrophic cardiomyopathy. Cardiovascular Pathology. 2003; 12(3): 14958. DOI: 10.1016/S1054-8807(03)00036-X
  19. Nakamura K, Kusano KF, Matsubara H, Nakamura Y, Miura A, Nishii N, et al. Relationship Between Oxidative Stress and Systolic Dysfunction in Patients with Hypertrophic Cardiomyopathy. Journal of Cardiac Failure. 2005; 11(2): 11723. DOI: 10.1016/j.cardfail.2004.05.005
  20. Dimitrow PP, Undas A, Wołkow P, Tracz W, Dubiel JS. Enhanced oxidative stress in hypertrophic cardiomyopathy. Pharmacological Reports. 2009; 61(3): 4915. DOI: 10.1016/S1734-1140(09)70091-X
  21. Kuusisto J, Karja V, Sipola P, Kholova I, Peuhkurinen K, Jaaskelainen P, et al. Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathy. Heart. 2012; 98(13): 100713. DOI: 10.1136/heartjnl-2011-300960
  22. Becker RC, Owens AP, 3rd, Sadayappan S. Tissue-level inflammation and ventricular remodeling in hypertrophic cardiomyopathy. J Thromb Thrombolysis. 2020; 49(2): 17783. DOI: 10.1007/s11239-019-02026-1
  23. Authors/Task Force m, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014; 35(39): 273379. DOI: 10.1093/eurheartj/ehu284
  24. Wang Z, Zhao L, He S. Prognostic nutritional index and the risk of mortality in patients with hypertrophic cardiomyopathy. Int J Cardiol. 2021; 331: 1527. DOI: 10.1016/j.ijcard.2021.01.023
  25. Liao H, Wang Z, Zhao L, Chen X, He S. Myocardial contraction fraction predicts mortality for patients with hypertrophic cardiomyopathy. Sci Rep. 2020; 10(1): 17026. DOI: 10.1038/s41598-020-72712-1
  26. He S, Wang Z, Cheem TH, Liao H, Chen X, He Y. External Validation of the Model of Thromboembolic Risk in Hypertrophic Cardiomyopathy Patients. Can J Cardiol. 2019; 35(12): 18006. DOI: 10.1016/j.cjca.2019.05.035
  27. Ho HH, Lee KL, Lau CP, Tse HF. Clinical characteristics of and long-term outcome in Chinese patients with hypertrophic cardiomyopathy. Am J Med. 2004; 116(1): 1923. DOI: 10.1016/j.amjmed.2003.09.020
  28. Lee CH, Liu PY, Lin LJ, Chen JH, Tsai LM. Clinical characteristics and outcomes of hypertrophic cardiomyopathy in Taiwan--a tertiary center experience. Clin Cardiol. 2007; 30(4): 17782. DOI: 10.1002/clc.20057
  29. Songsirisuk N, Kittipibul V, Methachittiphan N, Charoenattasil V, Zungsontiporn N, Spanuchart I, et al. Modes of death and clinical outcomes in adult patients with hypertrophic cardiomyopathy in Thailand. BMC Cardiovascular Disorders. 2019; 19(1). DOI: 10.1186/s12872-018-0984-0
  30. Coats CJ, Gallagher MJ, Foley M, O’Mahony C, Critoph C, Gimeno J, et al. Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy. Eur Heart J. 2013; 34(32): 252937. DOI: 10.1093/eurheartj/eht070
  31. Haruki S, Minami Y, Hagiwara N. Stroke and Embolic Events in Hypertrophic Cardiomyopathy: Risk Stratification in Patients Without Atrial Fibrillation. Stroke. 2016; 47(4): 93642. DOI: 10.1161/STROKEAHA.115.012130
  32. Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, et al. Sudden death in hypertrophic cardiomyopathy: identification of high-risk patients. J Am Coll Cardiol. 2000; 36(7): 22128. DOI: 10.1016/S0735-1097(00)01003-2
  33. Liu Q, Li D, Berger AE, Johns RA, Gao L. Survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis. Sci Rep. 2017; 7(1): 11957. DOI: 10.1038/s41598-017-12289-4
  34. Haneuse S, VanderWeele TJ, Arterburn D. Using the E-Value to Assess the Potential Effect of Unmeasured Confounding in Observational Studies. JAMA. 2019; 321(6): 6023. DOI: 10.1001/jama.2018.21554
  35. Alba AC, Agoritsas T, Walsh M, Hanna S, Iorio A, Devereaux PJ, et al. Discrimination and Calibration of Clinical Prediction Models: Users’ Guides to the Medical Literature. JAMA. 2017; 318(14): 137784. DOI: 10.1001/jama.2017.12126
  36. Hogye M, Mandi Y, Csanady M, Sepp R, Buzas K. Comparison of circulating levels of interleukin-6 and tumor necrosis factor-alpha in hypertrophic cardiomyopathy and in idiopathic dilated cardiomyopathy. Am J Cardiol. 2004; 94(2): 24951. DOI: 10.1016/j.amjcard.2004.03.078
  37. Zen K, Irie H, Doue T, Takamiya M, Yamano T, Sawada T, et al. Analysis of circulating apoptosis mediators and proinflammatory cytokines in patients with idiopathic hypertrophic cardiomyopathy: comparison between nonobstructive and dilated-phase hypertrophic cardiomyopathy. Int Heart J. 2005; 46(2): 23144. DOI: 10.1536/ihj.46.231
  38. Iwasaki J, Nakamura K, Matsubara H, Nakamura Y, Nishii N, Banba K, et al. Relationship between circulating levels of monocyte chemoattractant protein-1 and systolic dysfunction in patients with hypertrophic cardiomyopathy. Cardiovasc Pathol. 2009; 18(6): 31722. DOI: 10.1016/j.carpath.2008.12.004
  39. Zhu L, Zou Y, Wang Y, Luo X, Sun K, Wang H, et al. Prognostic Significance of Plasma High-Sensitivity C-Reactive Protein in Patients with Hypertrophic Cardiomyopathy. J Am Heart Assoc. 2017; 6(2). DOI: 10.1161/JAHA.116.004529
  40. Christiansen LB, Dela F, Koch J, Hansen CN, Leifsson PS, Yokota T. Impaired cardiac mitochondrial oxidative phosphorylation and enhanced mitochondrial oxidative stress in feline hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2015; 308(10): H123747. DOI: 10.1152/ajpheart.00727.2014
  41. Brites D. Bilirubin injury to neurons and glial cells: new players, novel targets, and newer insights. Semin Perinatol. 2011; 35(3): 11420. DOI: 10.1053/j.semperi.2011.02.004
  42. Wiedermann CJ. Anti-inflammatory activity of albumin. Crit Care Med. 2007; 35(3): 9812; author reply 2–3. DOI: 10.1097/01.CCM.0000257234.87784.91
  43. Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E. The antioxidant properties of serum albumin. FEBS Lett. 2008; 582(13): 17837. DOI: 10.1016/j.febslet.2008.04.057
  44. Afari ME, Bhat T. Neutrophil to lymphocyte ratio (NLR) and cardiovascular diseases: an update. Expert Rev Cardiovasc Ther. 2016; 14(5): 5737. DOI: 10.1586/14779072.2016.1154788
  45. Katipoglu Z, Mirza E, Oltulu R, Katipoglu B. May Monocyte/HDL Cholesterol Ratio (MHR) and Neutrophil/Lymphocyte Ratio (NLR) Be an Indicator of Inflammation and Oxidative Stress in Patients with Keratoconus? Ocul Immunol Inflamm. 2020; 28(4): 6326. DOI: 10.1080/09273948.2019.1611876
  46. Kubo T, Kitaoka H, Yamanaka S, Hirota T, Baba Y, Hayashi K, et al. Significance of high-sensitivity cardiac troponin T in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013; 62(14): 12529. DOI: 10.1016/j.jacc.2013.03.055
  47. Kehl DW, Buttan A, Siegel RJ, Rader F. Clinical utility of natriuretic peptides and troponins in hypertrophic cardiomyopathy. Int J Cardiol. 2016; 218: 2528. DOI: 10.1016/j.ijcard.2016.05.031
  48. Tardiff JC, Carrier L, Bers DM, Poggesi C, Ferrantini C, Coppini R, et al. Targets for therapy in sarcomeric cardiomyopathies. Cardiovascular Research. 2015; 105(4): 45770. DOI: 10.1093/cvr/cvv023
  49. Kundur AR, Singh I, Bulmer AC. Bilirubin, platelet activation and heart disease: a missing link to cardiovascular protection in Gilbert’s syndrome? Atherosclerosis. 2015; 239(1): 7384. DOI: 10.1016/j.atherosclerosis.2014.12.042
  50. Iba T, Hamakubo T, Nagaoka I, Sato K, Thachil J. Physiological Levels of Pentraxin 3 and Albumin Attenuate Vascular Endothelial Cell Damage Induced by Histone H3 In Vitro. Microcirculation. 2016; 23(3): 2407. DOI: 10.1111/micc.12269
  51. McCullough SA, Fifer MA, Mohajer P, Lowry PA, Reen CO, Baggish AL, et al. Clinical Correlates and Prognostic Value of Elevated Right Atrial Pressure in Patients with Hypertrophic Cardiomyopathy. Circ J. 2018; 82(5): 140511. DOI: 10.1253/circj.CJ-17-0959
  52. Lee HJ, Kim HK, Kim M, Moon I, Lee H, Kim BS, et al. Clinical impact of atrial fibrillation in a nationwide cohort of hypertrophic cardiomyopathy patients. Ann Transl Med. 2020; 8(21): 1386. DOI: 10.21037/atm-20-1817
DOI: https://doi.org/10.5334/gh.1163 | Journal eISSN: 2211-8179
Language: English
Submitted on: Apr 17, 2022
Accepted on: Sep 21, 2022
Published on: Oct 11, 2022
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2022 Ping Qiao, Liying Li, Haiyan Ruan, Muxin Zhang, Ziqiong Wang, Xinran Li, Rufeng Shi, Xin Wei, Linjia Duan, Yi Zheng, Sen He, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.